Scholarlink

Purpose <p>This study investigated the incidence and risk factors for postoperative nausea and vomiting (PONV) in patients receiving intravenous patient-controlled analgesia (IVPCA) with fentanyl, droperidol, and H1 antihistamine (PCA-DH) after laparoscopic gynecological surgery. Previous studies showed differing PONV incidence and risk factors between IVPCA containing droperidol (PCA-D) and that containing H<sub>1</sub> antihistamine (PCA-H). This study aims to assess whether the combination alters incidence or risk profiles.</p> Methods <p>We retrospectively analyzed patients who underwent laparoscopic gynecological surgery under general anesthesia and received PCA-DH. Multivariate logistic regression was used to evaluate associations between PONV and patient characteristics, anesthetic factors, and prophylactic antiemetic use.</p> Results <p>Among 3832 patients, the incidence of nausea, vomiting, and rescue antiemetic use was 14.6%, 4.0%, and 5.5%, respectively—lower than previously reported rates in PCA-D (36.6%, 17.6%, 17.7%) and PCA-H (26.5%, 8.7%, 11.0%). Additionally, the risk factors for PONV in PCA-DH differed from those identified in PCA-D and PCA-H studies.</p> Conclusion <p>IVPCA with both droperidol and H<sub>1</sub> antihistamine was associated with a reduced incidence of PONV. The findings suggest that this combination may effectively mitigate opioid-related PONV risk, and that risk factors may vary by IVPCA composition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient-controlled analgesia with droperidol and H1 antihistamine for prevention of postoperative nausea and vomiting after laparoscopic gynecological surgery: a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2025年9月14日

查看全文
  • Takehiko Nagaoka,
  • Toshiya Shiga,
  • Yoshinori Nakata

摘要

Purpose

This study investigated the incidence and risk factors for postoperative nausea and vomiting (PONV) in patients receiving intravenous patient-controlled analgesia (IVPCA) with fentanyl, droperidol, and H1 antihistamine (PCA-DH) after laparoscopic gynecological surgery. Previous studies showed differing PONV incidence and risk factors between IVPCA containing droperidol (PCA-D) and that containing H1 antihistamine (PCA-H). This study aims to assess whether the combination alters incidence or risk profiles.

Methods

We retrospectively analyzed patients who underwent laparoscopic gynecological surgery under general anesthesia and received PCA-DH. Multivariate logistic regression was used to evaluate associations between PONV and patient characteristics, anesthetic factors, and prophylactic antiemetic use.

Results

Among 3832 patients, the incidence of nausea, vomiting, and rescue antiemetic use was 14.6%, 4.0%, and 5.5%, respectively—lower than previously reported rates in PCA-D (36.6%, 17.6%, 17.7%) and PCA-H (26.5%, 8.7%, 11.0%). Additionally, the risk factors for PONV in PCA-DH differed from those identified in PCA-D and PCA-H studies.

Conclusion

IVPCA with both droperidol and H1 antihistamine was associated with a reduced incidence of PONV. The findings suggest that this combination may effectively mitigate opioid-related PONV risk, and that risk factors may vary by IVPCA composition.